The main finding of our study is, that the use of a GP IIb/IIIa inhibitor (eptifibatide) during endovascular treatment of cervical arterial dissections does not result in a higher incidence of unfavorable clinical outcome or intracranial hemorrhage compared to those who did not receive a GP IIb/IIIa inhibitor. This evidence concerns the gene ITGA2B and intracranial hemorrhage.